Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vaxxinity, Inc. (VAXX)

1.74   0 (0%) 11-25 12:56
Open: 1.74 Pre. Close: 1.74
High: 1.7455 Low: 1.7
Volume: 10,993 Market Cap: 195(M)

Technical analysis

as of: 2022-11-28 8:52:19 AM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.41     One year: 2.82
Support: Support1: 1.56    Support2: 1.25
Resistance: Resistance1: 2.06    Resistance2: 2.41
Pivot: 1.6
Moving Average: MA(5): 1.74     MA(20): 1.54
MA(100): 1.91     MA(250): 3.68
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 57.3     %D(3): 58.4
RSI: RSI(14): 56.3
52-week: High: 10.56  Low: 1.25
Average Vol(K): 3-Month: 174 (K)  10-Days: 144 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ VAXX ] has closed below upper band by 28.1%. Bollinger Bands are 28.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.75 - 1.76 1.76 - 1.76
Low: 1.68 - 1.69 1.69 - 1.7
Close: 1.72 - 1.74 1.74 - 1.75

Company Description

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Headline News

Sat, 26 Nov 2022
Died Suddenly Review: This anti-vaccine documentary needs to die suddenly - DailyO

Thu, 24 Nov 2022
Montana Supreme Court upholds anti-vaxx law for now, but sends the case back to district court – Daily Montanan - Daily Montanan

Wed, 23 Nov 2022
Nearly 40million children missed a measles vaccine last year amid lockdowns and anti-vaxx movement - Daily Mail

Tue, 22 Nov 2022
Letitia Wright Responds to 'THR' Story, Anti-Vaxx Statements - Vulture

Mon, 21 Nov 2022
RCMP monitored hostility from anti-vaxx movement against PM - CTV News

Mon, 21 Nov 2022
GO-VAXX bus heading to Angus on Tuesday - BarrieToday

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 112 (M)
% Held by Insiders 3.174e+007 (%)
% Held by Institutions 55.9 (%)
Shares Short 984 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.2183e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -250
Return on Assets (ttm) 985.7
Return on Equity (ttm) -67.2
Qtrly Rev. Growth 49000
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.79
Qtrly Earnings Growth -1.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -72 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 2896.19
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 850870
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.